author-photo

Iulian Pruteanu

Novartis

6

Papers

25

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

2019 Blood
Show All
- Source
- Cite
- Save
Citations (5)
Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)

2018 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (1)
Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

2018 Blood
Show All
- Source
- Cite
- Save
Citations (9)
Abstract CT110: Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)